New cocktail aims to knock out prostate cancer spread
NCT ID NCT04267887
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding apalutamide, abiraterone, and prednisone after chemotherapy can better control metastatic prostate cancer that still responds to hormone therapy. Seven men with high-risk, untreated disease are receiving this combination. The main goal is to see if prostate-specific antigen (PSA) levels drop to very low levels, indicating a strong response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide, abiraterone acetate, prednisone, and androgen deprivation therapy
What this could lead to
If successful, this combination could offer a more effective way to control advanced prostate cancer and delay its progression.
What could go wrong
This is a very small early-phase trial with only 7 participants, so results may not apply broadly. The drugs can cause side effects like fatigue, high blood pressure, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States